<DOC>
	<DOCNO>NCT00920218</DOCNO>
	<brief_summary>The purpose observer-blind study evaluate safety immunogenicity GlaxoSmithKline Biologicals ' investigational Herpes Zoster vaccine GSK1437173A administer 2 dos 3 dos hematopoietic stem cell transplant ( HCT ) recipient .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity GlaxoSmithKline Biologicals ' Herpes Zoster Vaccine 1437173A</brief_title>
	<detailed_description>The Protocol Posting update follow Protocol amendment 2 , Sep 2009 . The section impact : eligibility criterion .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol ; Male female subject least 18 year old time vaccination ; Serological evidence prior VZV infection subject bear 1980 late subject bear outside US 1980 tropical subtropical region . No test serological evidence prior VZV infection require US subject born 1980 ; Has undergone autologous HCT within past 5070 day treatment Hodgkin lymphoma , nonHodgkin lymphoma ( T B cell ) , myeloma acute myeloid leukemia , plan additional HCTs Written inform consent obtain subject ; If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period ; Administration plan administration vaccine part study protocol since transplantation . However license nonreplicating vaccine ( i.e . inactivate subunit vaccine , include inactivated subunit influenza vaccine , without adjuvant ) may administer 8 day prior dose 1 ; Administration immunoglobulins since transplantation ; Previous vaccination varicella HZ ; History HZ within previous 12 month ; Known exposure VZV since transplantation ; Evidence active infection time enrollment include temperature ≥ 37.5° C serious HCTrelated complication ; History allergic disease reaction likely exacerbate component vaccine ; Hypersensitivity intolerance acyclovir valacyclovir ; Pregnant lactate female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Stem cell transplantation</keyword>
	<keyword>Safety</keyword>
	<keyword>Herpes Zoster</keyword>
</DOC>